Observational studyAntimicrobial resistance and infection control2023
Microbiological trends and mortality risk factors of central line-associated bloodstream infections in an academic medical center 2015-2020.
Observational study in Antimicrobial resistance and infection control, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Prevalence and outcomes of central line-associated bloodstream infections in intensive care units in Saudi Arabia: a systematic review and meta-analysis.Frontiers in microbiology · 2026Pooled it
- Epidemiological Trends and Multidrug-Resistant Patterns in Central Line-Associated Bloodstream Infections Among Bone Marrow Transplant Patients at Comprehensive Cancer Center in Jordan: Five-Year Retrospective Study.Immunity, inflammation and disease · 2026Article
- Antimicrobial Peptides in Preventive Medicine: Current Perspectives on Coating Strategies.ACS infectious diseases · 2026Review
- Incidence, microbial profile and antimicrobial resistance trends of CLABSI in adult ICUs: a longitudinal prospective study.Iranian journal of microbiology · 2026Article
- The rise of WHO-priority pathogens in central line associated bloodstream infection: Challenging the AWaRe paradigm in critical care.World journal of microbiology & biotechnology · 2026Observational
- Temporal and anatomic determinants of central-line-associated bloodstream infection risk in a tertiary PICU: a 3-year time-to-event and competing-risk analysis.Frontiers in pediatrics · 2026Article
- Article
- Incidence and risk factors for hospital-attributable central line-associated bloodstream infections in adult inpatients in a tertiary hospital.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Surveillance of central-line-associated blood stream infections (CLABSI) in intensive care units of a tertiary care center in Western India.GMS hygiene and infection control · 2026Article
- Feasibility Study on Risk Stratification for Multidrug-Resistant Organism Infections Among ICU Patients in the United Arab Emirates.Risk management and healthcare policy · 2026Article
- Clinical and microbiological characteristics of bacteremia in pediatric intensive care unit: a retrospective analytical observational study.BMC pediatrics · 2025Observational
- Central venous catheter infections: building a causal model with expert domain knowledge to inform future clinical trials.Antimicrobial resistance and infection control · 2025Article
- Health Disparities in Central Line-Associated Bloodstream Infections: Analysis of the U.S. National Inpatient Sample Database (2016-2022).Infectious disease reports · 2025Article
- Effect of catheter dwell time on the risk of central line-associated bloodstream infections in central venous catheters and peripherally inserted central catheters.Antimicrobial resistance and infection control · 2025Article
- Patterns and Predictors ofJournal of fungi (Basel, Switzerland) · 2025Article
- Outcome of Bloodstream Infections Caused by Antibiotic-Resistant Bacteria: A 7-Year Retrospective Study at the University Hospital of Palermo, Italy.Antibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Lock Therapy: A Strategy for Managing Catheter-Related Bacteremia.Antibiotics (Basel, Switzerland) · 2025Article
- Incidence, Compliance, and Risk Factor Associated with Central Line-Associated Bloodstream Infection (CLABSI) in Intensive Care Unit (ICU) Patients: A Multicenter Study in an Upper Middle-Income Country.Antibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Lock Therapy in Clinical Practice: A Scoping Review.Microorganisms · 2025Review
- Dynamic shifts in pathogen ecology of catheter-related bloodstream infections: temporal trends and ward-specific risk landscapes.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite tremendous efforts to prevent central line-associated bloodstream infections, they still remain life-threatening complications among hospitalized patients with significant morbidity and mortality worldwide. The emerging antibiotic-resistant bacteria and other risk factors, including patient comorbidities, complicate patient management.
methodsA single-center retrospective observational study was conducted at King Fahad Hospital of the University, Eastern Province, Saudi Arabia. Hospitalized patients with confirmed central line-associated bloodstream infections between January 2015 and December 2020 were included. The primary objectives were to investigate the trends in antibiotic susceptibility patterns of the causative agents, coexisting comorbid conditions, and other risk factors associated with mortality.
resultsA total of 214 patients with confirmed central line-associated bloodstream infections were included (CLABSI). The overall 30-day mortality rate was 33.6%. The infection rates per 1000 central line days for medical, surgical, and pediatric intensive care units were 4.97, 2.99, and 4.56 per 1000 CL days, respectively. The overall microbiological trends showed a predominance of Gram-negative agents, a steady increase of fungal CLABSI up to 24.0% in 2020, and a high prevalence of multidrug resistance up to 47% of bacterial CLABSI. In addition, the study indicates a significant negative surviving correlation with diabetes mellitus, cardiovascular disease, lung disease, chronic kidney disease, and the presence of ≥ 3 comorbidities (P < 0.05).
conclusionThe microbiological trends of the study population demonstrated a steady increase of CLABSI caused by Candida spp. with a predominance of Gram-negative pathogens. Stratifying the patients according to relevant mortality risk factors, including patient comorbidities, will help reduce CLABSI rates and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.